Literature DB >> 23370767

Expression profiling of 519 kinase genes in matched malignant peripheral nerve sheath tumor/plexiform neurofibroma samples is discriminatory and identifies mitotic regulators BUB1B, PBK and NEK2 as overexpressed with transformation.

Thomas P Stricker1, Kammi J Henriksen, James H Tonsgard, Anthony G Montag, Thomas N Krausz, Peter Pytel.   

Abstract

About 50% of all malignant peripheral nerve sheath tumors (MPNSTs) arise as neurofibromatosis type 1 associated lesions. In those patients malignant peripheral nerve sheath tumors are thought to arise through malignant transformation of a preexisting plexiform neurofibroma. The molecular changes associated with this transformation are still poorly understood. We sought to test the hypothesis that dysregulation of expression of kinases contributes to this malignant transformation. We analyzed expression of all 519 kinase genes in the human genome using the nanostring nCounter system. Twelve cases of malignant peripheral nerve sheath tumor arising in a background of preexisting plexiform neurofibroma were included. Both components were separately sampled. Statistical analysis compared global changes in expression levels as well as changes observed in the pairwise comparison of samples taken from the same surgical specimen. Immunohistochemical studies were performed on tissue array slides to confirm expression of selected proteins. The expression pattern of kinase genes can separate malignant peripheral nerve sheath tumors and preexisting plexiform neurofibromas. The majority of kinase genes is downregulated rather than overexpressed with malignant transformation. The patterns of expression changes are complex without simple recurring alteration. Pathway analysis demonstrates that differentially expressed kinases are enriched for kinases involved in the direct regulation of mitosis, and several of these show increased expression in malignant peripheral nerve sheath tumors. Immunohistochemical studies for the mitotic regulators BUB1B, PBK and NEK2 confirm higher expression levels at the protein level. These results suggest that the malignant transformation of plexiform neurofibroma is associated with distinct changes in the expression of kinase genes. The patterns of these changes are complex and heterogeneous. There is no single unifying alteration. Kinases involved in mitotic regulation are particularly enriched in the pool of differentially expressed kinases. Some of these are overexpressed and are therefore possible targets for kinase inhibitors.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23370767     DOI: 10.1038/modpathol.2012.242

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  15 in total

1.  Validation of a prognostic multi-gene signature in high-risk neuroblastoma using the high throughput digital NanoString nCounter™ system.

Authors:  Thomas P Stricker; Andres Morales La Madrid; Alexandre Chlenski; Lisa Guerrero; Helen R Salwen; Yasmin Gosiengfiao; Elizabeth J Perlman; Wayne Furman; Armita Bahrami; Jason M Shohet; Peter E Zage; M John Hicks; Hiroyuki Shimada; Rie Suganuma; Julie R Park; Sara So; Wendy B London; Peter Pytel; Kirsteen H Maclean; Susan L Cohn
Journal:  Mol Oncol       Date:  2014-01-31       Impact factor: 6.603

Review 2.  Targeting NEK2 as a promising therapeutic approach for cancer treatment.

Authors:  Yanfen Fang; Xiongwen Zhang
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

3.  Expression of PBK/TOPK in cervical cancer and cervical intraepithelial neoplasia.

Authors:  Qiong Luo; Bin Lei; Shuguang Liu; Yaowen Chen; Wenjie Sheng; Peixin Lin; Wenxia Li; Haili Zhu; Hong Shen
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

4.  Treatment of neurofibromatosis type 1.

Authors:  Caterina Sabatini; Donatella Milani; Francesca Menni; Gianluca Tadini; Susanna Esposito
Journal:  Curr Treat Options Neurol       Date:  2015-06       Impact factor: 3.598

5.  Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival.

Authors:  Arjen H G Cleven; Ghadah A Al Sannaa; Inge Briaire-de Bruijn; Davis R Ingram; Matt van de Rijn; Brian P Rubin; Maurits W de Vries; Kelsey L Watson; Keila E Torres; Wei-Lien Wang; Sjoerd G van Duinen; Pancras C W Hogendoorn; Alexander J Lazar; Judith V M G Bovée
Journal:  Mod Pathol       Date:  2016-03-18       Impact factor: 7.842

6.  RABL6A Is an Essential Driver of MPNSTs that Negatively Regulates the RB1 Pathway and Sensitizes Tumor Cells to CDK4/6 Inhibitors.

Authors:  Jordan L Kohlmeyer; Courtney A Kaemmer; Casey Pulliam; Chandra K Maharjan; Allison Moreno Samayoa; Heather J Major; Kendall E Cornick; Vickie Knepper-Adrian; Rajesh Khanna; Jessica C Sieren; Mariah R Leidinger; David K Meyerholz; K D Zamba; Jill M Weimer; Rebecca D Dodd; Benjamin W Darbro; Munir R Tanas; Dawn E Quelle
Journal:  Clin Cancer Res       Date:  2020-02-21       Impact factor: 12.531

7.  Gene expression profiling informs HPV cervical histopathology but not recurrence/relapse after LEEP in ART-suppressed HIV+HPV+ women.

Authors:  Emmanouil Papasavvas; Andrew V Kossenkov; Livio Azzoni; Nicola M Zetola; Agnieszka Mackiewicz; Brian N Ross; Matthew Fair; Surya Vadrevu; Doreen Ramogola-Masire; Ian Sanne; Cynthia Firnhaber; Luis J Montaner
Journal:  Carcinogenesis       Date:  2019-04-29       Impact factor: 4.944

Review 8.  Role of NEK2A in human cancer and its therapeutic potentials.

Authors:  Jiliang Xia; Reinaldo Franqui Machin; Zhimin Gu; Fenghuang Zhan
Journal:  Biomed Res Int       Date:  2015-02-01       Impact factor: 3.411

9.  TAGLN expression is upregulated in NF1-associated malignant peripheral nerve sheath tumors by hypomethylation in its promoter and subpromoter regions.

Authors:  Gun-Hoo Park; Su-Jin Lee; Hyunee Yim; Jae-Ho Han; Hyon J Kim; Young-Bae Sohn; Jung Min Ko; Seon-Yong Jeong
Journal:  Oncol Rep       Date:  2014-08-04       Impact factor: 3.906

10.  PBK/TOPK Expression Predicts Prognosis in Oral Cancer.

Authors:  Chin-Fang Chang; Sung-Lang Chen; Wen-Wei Sung; Ming-Ju Hsieh; Hui-Ting Hsu; Li-Hsin Chen; Mu-Kuan Chen; Jiunn-Liang Ko; Chih-Jung Chen; Ming-Chih Chou
Journal:  Int J Mol Sci       Date:  2016-06-24       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.